C6 Ceramide Inhibits Canine Mammary Cancer Growth and Metastasis by Targeting EGR3 through JAK1/STAT3 Signaling
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.C6 ceramide, a tumor suppressor, inhibits canine mammary cancer growth and metastasis. It targets EGR3 by regulating the JAK1/STAT3 pathway, offering a potential new treatment strategy for canine mammary tumors.
Area Of Science
- Veterinary Oncology
- Cancer Biology
- Molecular Medicine
Background
- Canine mammary tumors are a significant clinical challenge due to high incidence and metastasis.
- Short-chain sphingolipid C6 ceramide shows tumor suppressor potential, but its role in canine mammary cancer is unknown.
Purpose Of The Study
- To investigate the role of C6 ceramide in canine mammary cancer progression.
- To explore the underlying molecular mechanisms of C6 ceramide's anti-tumor effects.
Main Methods
- In vitro studies on canine mammary cancer cells (CHMp cells).
- In vivo studies using animal models.
- Analysis of cell cycle, apoptosis, migration, and invasion.
- Investigation of EGR3, JAK1/STAT3 signaling pathway.
Main Results
- C6 ceramide inhibited canine mammary cancer cell growth by regulating the cell cycle, not apoptosis.
- C6 ceramide reduced cell migration and invasion in vitro.
- In vivo, C6 ceramide decreased tumor growth and lung metastasis without adverse effects.
- Knockdown of EGR3 increased proliferation and migration via JAK1/STAT3 pathway activation.
Conclusions
- C6 ceramide inhibits canine mammary cancer growth and metastasis by targeting EGR3.
- The mechanism involves the regulation of the JAK1/STAT3 signaling pathway.
- EGR3 presents a novel therapeutic target for canine mammary cancer treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...